Multiple sclerosis (MS) treatments developed by Biogen (Nasdaq: BIIB) have featured in data presentations at the annual congress of the American Academy of Neur 5 April 2022
At AMCP 2022 in Chicago, new data from Janssen, the pharma arm of Johnson & Johnson (NYSE: JNJ), support the value of switching certain people with schizophreni 31 March 2022
At this year’s annual congress of the American Academy of Dermatology (AAD), Incyte (Nasdaq: INCY) has announced new one-year results for Opzelura (ruxolitinib) 28 March 2022
French drugmaker Sanofi and partner Regeneron have announced positive results from the Phase III PRIME2 trial of Dupixent (dupilumab) at the American Academy of 28 March 2022
A commercial stage biopharmaceutical R&D company, focused on the development of products that address the medical challenges in the therapeutic area of anti-infectives.